Literature DB >> 16181614

Brain-derived neurotrophic factor and autoantibodies to neural antigens in sera of children with autistic spectrum disorders, Landau-Kleffner syndrome, and epilepsy.

Anne M Connolly1, Michael Chez, Elizabeth M Streif, Richard M Keeling, Paul T Golumbek, Jennifer M Kwon, James J Riviello, Ricki G Robinson, Rosalind J Neuman, Ruth Mary K Deuel.   

Abstract

BACKGROUND: Brain derived neurotrophic factor (BDNF) elevation in newborn sera predicts intellectual/social developmental abnormalities. Other autoantibodies (AAs) to endothelial cells (ECs) and myelin basic protein (MBP) are also elevated in some children. We tested relationships between BDNF, BDNF AAs, and other AAs in children with these disorders.
METHODS: BDNF levels and IgG/IgM autoantibodies to BDNF, ECs, MBP, and histones were measured in children with autism, childhood disintegrative disorder (CDD), pervasive developmental delay-not otherwise specified (PDD-nos), acquired epilepsy, Landau-Kleffner syndrome (LKS); healthy children (HC), and children with non-neurological illnesses (NNI).
RESULTS: Mean BDNF levels were elevated in children with autism and CDD, (p < or = 0.0002) compared to HC or NNI. Mean IgG and IgM BDNF AAs were elevated in children with autism, CDD and epilepsy (p < or = 0.0005) compared to HC but not to NNI. Mean IgM AA EC titers detected by immunocytochemistry were higher in autism, PDD-NOS, epilepsy, and LKS (p < or = 0.005) compared to HC and NNI. While mean ELISA IgG EC AAs were higher in autism and PPD-NOS (p < 0.005) compared to HC but not NNI, ELISA IgM EC AAs were higher in children with autism, CDD, PDD-NOS, and epilepsy compared to both HC and NNI (p < 0.0005). Mean anti-MBP IgG and IgM titers were higher in all study groups (p < 0.005) except for LKS compared to both HC and NNI.
CONCLUSION: Children with developmental disorders and epilepsy have higher AAs to several neural antigens compared to controls. The presence of both BDNF AAs and elevated BDNF levels in some children with autism and CDD suggests a previously unrecognized interaction between the immune system and BDNF.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16181614     DOI: 10.1016/j.biopsych.2005.07.004

Source DB:  PubMed          Journal:  Biol Psychiatry        ISSN: 0006-3223            Impact factor:   13.382


  79 in total

1.  Decreased serum BDNF levels in patients with epileptic and psychogenic nonepileptic seizures.

Authors:  W C LaFrance; K Leaver; E G Stopa; G D Papandonatos; A S Blum
Journal:  Neurology       Date:  2010-10-05       Impact factor: 9.910

Review 2.  Immune dysfunction in autism: a pathway to treatment.

Authors:  Milo Careaga; Judy Van de Water; Paul Ashwood
Journal:  Neurotherapeutics       Date:  2010-07       Impact factor: 7.620

Review 3.  Immune therapy in autism: historical experience and future directions with immunomodulatory therapy.

Authors:  Michael G Chez; Natalie Guido-Estrada
Journal:  Neurotherapeutics       Date:  2010-07       Impact factor: 7.620

Review 4.  Early pharmacological treatment of autism: a rationale for developmental treatment.

Authors:  Terrence C Bethea; Linmarie Sikich
Journal:  Biol Psychiatry       Date:  2007-02-15       Impact factor: 13.382

5.  Differential monocyte responses to TLR ligands in children with autism spectrum disorders.

Authors:  Amanda M Enstrom; Charity E Onore; Judy A Van de Water; Paul Ashwood
Journal:  Brain Behav Immun       Date:  2009-08-08       Impact factor: 7.217

6.  Family analysis of immunoglobulin classes and subclasses in children with autistic disorder.

Authors:  Mirko Spiroski; Vladimir Trajkovski; Dejan Trajkov; Aleksandar Petlichkovski; Olivija Efinska-Mladenovska; Slavica Hristomanova; Eli Djulejic; Meri Paneva; Jadranka Bozhikov
Journal:  Bosn J Basic Med Sci       Date:  2009-11       Impact factor: 3.363

Review 7.  Regression in autistic spectrum disorders.

Authors:  Gerry A Stefanatos
Journal:  Neuropsychol Rev       Date:  2008-10-28       Impact factor: 7.444

Review 8.  Exploring the multifactorial nature of autism through computational systems biology: calcium and the Rho GTPase RAC1 under the spotlight.

Authors:  Fares Zeidán-Chuliá; José Luiz Rybarczyk-Filho; Alla B Salmina; Ben-Hur Neves de Oliveira; Mami Noda; José Cláudio F Moreira
Journal:  Neuromolecular Med       Date:  2013-03-02       Impact factor: 3.843

9.  Immune Endophenotypes in Children With Autism Spectrum Disorder.

Authors:  Milo Careaga; Sally Rogers; Robin L Hansen; David G Amaral; Judy Van de Water; Paul Ashwood
Journal:  Biol Psychiatry       Date:  2015-09-11       Impact factor: 13.382

Review 10.  Does PGC1α/FNDC5/BDNF Elicit the Beneficial Effects of Exercise on Neurodegenerative Disorders?

Authors:  Mohammad Jodeiri Farshbaf; Kamran Ghaedi; Timothy L Megraw; Jennifer Curtiss; Mahsa Shirani Faradonbeh; Pooneh Vaziri; Mohammad Hossein Nasr-Esfahani
Journal:  Neuromolecular Med       Date:  2015-11-26       Impact factor: 3.843

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.